Misonix Incorporated Trains Surgeons On The BoneScalpel™ At The 2014 North American Spine Society Annual Meeting

FARMINGDALE, N.Y., Nov. 19, 2014 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international ultrasonic surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic instruments for spine surgery, neurosurgery and other surgical specialties, announced that it trained more than 50 leading spine surgeons on the BoneScalpel system last week at the North American Spine Society ("NASS") annual meeting in San Francisco, CA.

"The Misonix team along with BoneScalpel key opinion leaders successfully demonstrated and trained both domestic and international surgeons on the use and benefits of the BoneScalpel in spine surgery," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix.

"The Misonix booth was well attended by my surgeon colleagues," noted Dr. Juan Uribe, University of South Florida, Tampa, FL. "The BoneScalpel was one of very few spinal devices showcased at NASS that has the potential to modify spine surgeons' practice." 

At the tradeshow booth, during several "Meet the Expert" sessions, key opinion leaders presented the BoneScalpel System and its benefits as an ultrasonic device providing surgeons with a clean, controlled bone incision and removal that is also soft-tissue sparing. 

"Spine surgeons learned the techniques and benefits of using the BoneScalpel in several different spinal procedures at NASS this year," commented Dr. Nicholas Renaldo, Vassar Brothers Medical Center, Poughkeepsie, NY.  Dr. Renaldo added, "In my practice, I use the BoneScalpel in most of my procedures as it reduces bone bleeding and offers soft-tissue protection." 

The Bone Scalpel was also featured at the NASS Solution Showcase with presentations by renowned spine surgeons: Dr. Nicholas Renaldo, Vassar Brothers Medical Center, Poughkeepsie, NY. and Dr. Shane Burch, the University of California Medical Center, San Francisco, CA.

Mr. McManus concluded, "The Misonix team will work with the newly-trained surgeons to place BoneScalpel systems in their institutions in the upcoming weeks and months.  We will capitalize on the additional momentum that attending this key meeting has provided us to meet important leading spine surgeons from around the world and to have the opportunity to follow up with training for many new potential users. "

About Misonix

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery,   wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's Web site at www.misonix.com.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

SOURCE Misonix, Inc.